Literature DB >> 12429227

Behavioral and anatomical effects of long-term L-dihydroxyphenylalanine (L-DOPA) administration in rats with unilateral lesions of the nigrostriatal system.

Anna Mura1, Matti Mintz, Joram Feldon.   

Abstract

This study investigated behavioral and anatomical changes induced by long periods of L-DOPA treatment in the unilateral rat model of Parkinson's disease. After daily injections of L-DOPA (50 mg/kg, ip) given for 1, 4, 8, or 16 weeks, behavioral sensitization, expressed by contralateral turning and changes in its pattern, increased within the first week of treatment and remained unchanged thereafter. Dyskinetic movements, affecting the trunk and limbs of all treated rats, also developed within the first week of treatment and increased further during the 16 weeks of L-DOPA treatment. L-DOPA responsiveness was also accompanied by changes at the neuronal level, as shown by changes in the expression of c-fos in the dopamine-depleted striatum. Following 1 week of L-DOPA treatment there was a marked decrease in striatal c-fos expression, compared to single injections, especially evident in the medial and ventral regions and to a lesser extent in the dorsolateral regions of the striatum. This specific regional expression of c-fos was maintained throughout the 16 weeks of L-DOPA treatment. Overall, our results show that behavioral sensitization to L-DOPA starts relatively early during the treatment and include not only an increase in contralateral turning rate but also an increase in dyskinetic movements. Persisting c-fos expression in the dorsolateral striatum might be implicated in the development of dyskinesias when L-DOPA treatment is extended for periods longer than 1 week.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12429227     DOI: 10.1006/exnr.2002.7976

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  12 in total

1.  Role of the primary motor cortex in L-Dopa-induced dyskinesia and its modulation by 5-HT1A receptor stimulation.

Authors:  Corinne Y Ostock; Kristin B Dupre; Karen L Eskow Jaunarajs; Hannah Walters; Jessica George; David Krolewski; Paul D Walker; Christopher Bishop
Journal:  Neuropharmacology       Date:  2011-05-27       Impact factor: 5.250

2.  Functional interaction between mGlu 5 and NMDA receptors in a rat model of Parkinson's disease.

Authors:  Nathalie Turle-Lorenzo; Nathalie Breysse; Christelle Baunez; Marianne Amalric
Journal:  Psychopharmacology (Berl)       Date:  2005-02-22       Impact factor: 4.530

3.  The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism.

Authors:  Melanie A Paquette; Katherine Foley; Elizabeth G Brudney; Charles K Meshul; Steven W Johnson; S Paul Berger
Journal:  Psychopharmacology (Berl)       Date:  2009-03-13       Impact factor: 4.530

4.  PI3 kinase/Akt activation mediates estrogen and IGF-1 nigral DA neuronal neuroprotection against a unilateral rat model of Parkinson's disease.

Authors:  Arnulfo Quesada; Becky Y Lee; Paul E Micevych
Journal:  Dev Neurobiol       Date:  2008-04       Impact factor: 3.964

5.  Exogenous corticosterone reduces L-DOPA-induced dyskinesia in the hemi-parkinsonian rat: role for interleukin-1beta.

Authors:  C J Barnum; K L Eskow; K Dupre; P Blandino; T Deak; C Bishop
Journal:  Neuroscience       Date:  2008-07-12       Impact factor: 3.590

6.  Alterations in primary motor cortex neurotransmission and gene expression in hemi-parkinsonian rats with drug-induced dyskinesia.

Authors:  D Lindenbach; M M Conti; C Y Ostock; K B Dupre; C Bishop
Journal:  Neuroscience       Date:  2015-09-09       Impact factor: 3.590

7.  Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats.

Authors:  Christopher Bishop; David M Krolewski; Karen L Eskow; Christopher J Barnum; Kristin B Dupre; Terrence Deak; Paul D Walker
Journal:  J Neurosci Res       Date:  2009-05-15       Impact factor: 4.164

8.  Striatal output markers do not alter in response to circling behaviour in 6-OHDA lesioned rats produced by acute or chronic administration of the monoamine uptake inhibitor BTS 74 398.

Authors:  E L Lane; S Cheetham; P Jenner
Journal:  J Neural Transm (Vienna)       Date:  2008-02-04       Impact factor: 3.575

9.  Neuroprotective effect of a new DJ-1-binding compound against neurodegeneration in Parkinson's disease and stroke model rats.

Authors:  Yoshihisa Kitamura; Shotaro Watanabe; Masanobu Taguchi; Kentaro Takagi; Takuya Kawata; Kazuko Takahashi-Niki; Hiroyuki Yasui; Hiroshi Maita; Sanae Mm Iguchi-Ariga; Hiroyoshi Ariga
Journal:  Mol Neurodegener       Date:  2011-07-08       Impact factor: 14.195

Review 10.  Animal models of Parkinson's disease and L-dopa induced dyskinesia: how close are we to the clinic?

Authors:  Emma Lane; Stephen Dunnett
Journal:  Psychopharmacology (Berl)       Date:  2007-09-25       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.